Complex Regional Pain Syndrome Pipeline|Clinical Trials | Key Companies

Complex Regional Pain Syndrome Pipeline|Clinical Trials | Key Companies
DelveInsight Business Research LLP
Complex regional pain syndromes- Pipeline Insight, 2023″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complex regional pain syndromes pipeline landscape is provided which includes the disease overview and Complex regional pain syndromes treatment guidelines.

Complex regional pain syndromes- Pipeline Insight, 2023” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complex regional pain syndromes pipeline landscape is provided which includes the disease overview and Complex regional pain syndromes treatment guidelines. The assessment part of the report embraces, in depth Complex regional pain syndromes commercial assessment and clinical assessment of the pipeline products under development. In the report, a detailed description of the drug is given which includes a mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complex regional pain syndromes collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Some of the Key Highlights of Complex Regional Pain Syndrome Pipeline 

  • The Key Companies working in Complex Regional Pain Syndrome pipeline are as follows Takeda, Tryp Therapeutics, Soin Therapeutics and many others.
  • The Key Therapies included are Soticlestat, TRP-8803, and many others 

 

Got queries? Click here to learn more about the Complex Regional Pain Syndrome Pipeline

Complex Regional Pain Syndrome Overview

Complex regional pain syndrome is a broad term describing excess and prolonged pain and inflammation that follows an injury to an arm or leg or any part of the body. CRPS is clinically characterized by sensory, autonomic, and motor disturbances; it can affect any part of the body, but occurs most often in the extremities. The wrist is most frequently affected after distal radial fractures. Complex regional pain syndrome can develop after different types of injuries, such as sprains and strains, surgeries, fractures, contusions, nerve lesions, stroke, etc. Complex Regional Pain Syndrome has acute (recent, short-term) and chronic (lasting greater than six months) forms. Besides the increased perception of pain, other signs and symptoms that are seen with Complex Regional Pain Syndrome, particularly in its early stages are a warm, red, and swollen extremity on the affected side.

There are two types of Complex Regional Pain Syndrome, Type I occurs after an illness or injury that did not directly damage a nerve in the affected area, and Type II follows a distinct nerve injury.

Complex Regional Pain Syndrome  Epidemiological Segmentation 

1 Complex Regional Pain Syndrome Total Prevalent Cases 

2 Complex Regional Pain Syndrome Total Diagnosed Prevalent cases

3 Complex Regional Pain Syndrome Age-specific Diagnosed Prevalent Cases

4 Complex Regional Pain Syndrome Type-specific Diagnosed Prevalent Cases 

Major Players in Complex Regional Pain Syndromes

There are approx. 3+ key companies that are developing therapies for Complex regional pain syndromes. The companies that have their Complex regional pain syndromes drug candidates in the most advanced stage, i.e. Phase II, Takeda.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Complex regional pain syndromes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Learn more by requesting for sample @ Complex Regional Pain Pipeline 

 

Table of Contents

1. Key Insights 

2. Report Introduction 

3 Executive Summary of Complex Regional Pain Syndrome 

4 Disease Background and Overview

5 Epidemiology and patient population

6 The United States 

7 EU 5

8 Complex Regional Pain Syndrome  Emerging Therapies

9. Complex Regional Pain Syndrome Market Outlook

10. Market Access and Reimbursement of Therapies

11. Appendix

12. Hemophilia Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

Click here to read more about Complex Regional Pain Syndrome 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services